Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | PAM | P19021 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158360 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP2A6MAOBHTR2ATSHR | |
| SCHEMBL8838345 | 0.87 | TP53 (0.38) | ALDH1A1MAOBIDO1L3MBTL1 | |
| SCHEMBL11070730 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP2A6MAOBHTR2ATSHR | |
| SCHEMBL9784248 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CYP2A6MAOBHTR2ATSHR | |
| SCHEMBL295172 | 0.78 | HTR2A (0.50) | MAOBHTR2AIDO1PAMSIGMAR1 | |
| SCHEMBL21457936 | 0.78 | HTR2A (0.50) | MAOBHTR2AIDO1PAMSIGMAR1 | |
| SCHEMBL9491843 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CYP2A6MAOBHTR2ATSHR | |
| SCHEMBL21457935 | 0.78 | HTR2A (0.50) | MAOBHTR2AIDO1PAMSIGMAR1 | |
| SCHEMBL2142092 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP2A6MAOBTSHRIDO1 | |
| SCHEMBL7736539 | 0.77 | IDO1 (0.52) | ALDH1A1CYP2A6MAOBHTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-4789754-A | PRODUCTION OF CHRYSANTHEMIC ESTERS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-12-06 | — | — | US | disclosed |
| US-4594355-A | Phenyl ring with a 2,2-dimethylcyclopropanecarboxylic group on ring and a dihalovinyl group in position 3 | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | ALDH1A1 187/4885CYP2A6 296/4885MAOB 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.